- Introducing a new portfolio of heart valve products aiming to restore health 
and extend life

OrbusNeich and P+F today announced they have entered into an agreement for the 
exclusive distribution and manufacturing of a range of innovative minimally 
invasive heart valve products in the Asia Pacific region, including China, 
Japan, Taiwan, South Korea, Hong Kong, Singapore, Malaysia, Australia and New 
Zealand.

P+F will bring to the partnership a series of innovative minimally invasive 
heart valve products premounted on the delivery system using P+F's proprietary 
dry valve technology. The product portfolio includes the TricValve(R) 
Transcatheter Bicaval Valves and the Vienna Aortic Self-Expandable Transcather 
Valve complemented by transcatheter solutions for pulmonary and mitral valve 
disease as well as endovascular grafts.

The TricValve(R) Transcatheter Bicaval Valves is a system of two self-expanding 
biological valves for the treatment of patients with hemodynamically relevant 
tricuspid insufficiency and caval reflux, specifically intended for patients at 
extreme risk or who are unsuitable for open heart surgery.

The Vienna Aortic Self-Expandable Transcatheter Valve is designed to treat 
severe aortic stenosis in patients at medium to high risk for open heart 
surgery. The minimally invasive valve replaces the native aortic valve without 
the need for concomitant surgical removal. Both systems are pending CE mark 
approval.

"We are delighted to collaborate with P+F and to establish a strong presence in 
a large and fast-growing transcatheter heart valve market in Asia Pacific. Both 
China and Japan face the challenge of a growing elderly patient population with 
the prevalence of moderate-to-severe dysfunctional heart valves. Our unique 
product line for percutaneous transcatheter based therapeutics will result in 
significant improvement of health-related quality of life to our patients, 
which is an important measure of procedural success in the elderly," said David 
Chien, Chairman, President and CEO, OrbusNeich.

"This joint venture brings us one step closer to providing patients in Asia 
Pacific with P+F's transformational heart valve solutions and supports our 
strategy of rapid expansion into key, fast-growing markets, globally. It is the 
right moment to focus on being the leading player in this region," said 
Siegfried Einhellig, President and COO of P+F.

Katharina Kiss, CEO of P+F, commented: "Partnering with OrbusNeich is an ideal 
opportunity for us to expand our vision by bringing our innovative heart valves 
technology to patients. My mission as a cardiologist is not only to save lives 
but to ensure the maximum quality of life for each of our patients and I am 
convinced that with the joint efforts of this newly founded Asian joint venture 
we will be able to revolutionize the medical landscape."

"This powerful partnership supports our strategic business directive to add 
important complementary structural heart devices to our coronary and peripheral 
portfolio. We look forward to working with P+F to expand the potential of our 
combined strengths in the global medical device business," said Alain Khair, 
Senior Vice President and Chief Commercial Officer of OrbusNeich.

About OrbusNeich 

OrbusNeich is a global pioneer in the provision of life-changing vascular 
solutions and offers an extensive portfolio of products that set industry 
benchmarks in vascular intervention. Current products include the world's first 
dual therapy stents, the COMBO(R) Plus and COMBO(R) Dual Therapy Stents, 
together with coronary stents, speciality balloons, balloons, and 
microcatheters marketed under the names of Azule(R), Scoreflex(R), Scoreflex(R) 
NC, Sapphire(R), Sapphire(R) II, Sapphire(R) II PRO, Sapphire(R) 3, Sapphire(R) 
NC, Sapphire(R) NC Plus, Sapphire(R) II NC, Sapphire(R) NC 24, Teleport(R) and 
Teleport(R) Control as well as products to treat peripheral artery disease: the 
Jade(R) and Scoreflex(R) PTA balloons.

OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; 
Fort Lauderdale, Florida, USA; Hoevelaken, The Netherlands; Zuchwil, 
Switzerland; and regional sales offices in Germany, France, Switzerland, Spain, 
Japan, Hong, Singapore; and Malaysia. OrbusNeich supplies medical devices to 
physicians in more than 60 countries. For more information, visit 
www.OrbusNeich.com.

About P+F Products and Features 

With more than 25 years of experience in the medical field, the leadership team 
of P+F has built a complete infrastructure for research, development, 
manufacture, and distribution in order to deliver significant innovations and 
add value to its customers and patients. P+F is striving to become the 
"standard of comparison" in the development of state-of-the-art innovative 
technologies in the field of cardiology products that contribute to human 
welfare by the application of biomedical engineering in the research, 
development and manufacture of devices which restore health, extend life and 
are accessible to all.

The company's lead product, TricValve(R), is currently undergoing the CE 
certification process. TricValve(R) is a bicaval, biological, minimally 
invasive valves system for the treatment of severe tricuspid insufficiency. The 
further pipeline includes biological heart valves like the TAVI system Vienna 
Aortic Self-Expandable Transcatheter Valve, a Pulmonary Valve and Mitral Valve 
as well as Aortosave(R), a minimally invasive device to treat Type A aortic 
dissections, as well as the full portfolio of endovascular grafts. The 
proprietary Dry Pericardium technology platform enables off the shelf use of 
the company's heart valves.

Headquartered in Vienna, Austria, under the leadership of Prof Dr Katharina 
Kiss and Prof Dr Siegfried Einhellig, P+F coordinates worldwide operations. For 
more information, visit www.productsandfeatures.com.

Source: OrbusNeich